Vega Investment Solutions acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,164 shares of the biopharmaceutical company's stock, valued at approximately $1,349,000.
Several other large investors have also added to or reduced their stakes in REGN. Aberdeen Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter valued at about $41,000. Algert Global LLC bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at about $490,000. Maxi Investments CY Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $1,871,000. Portland Investment Counsel Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $408,000. Finally, Cibc World Market Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $13,597,000. Institutional investors own 83.31% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Canaccord Genuity Group reduced their price objective on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a "buy" rating for the company in a research note on Tuesday, May 19th. HSBC cut their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a "buy" rating for the company in a report on Monday, July 6th. Leerink Partners upped their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a report on Monday, August 17th. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a "sector perform" rating in a report on Friday, July 31st. Finally, Barclays lowered their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an "overweight" rating on the stock in a research report on Thursday, April 30th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $801.70.
Read Our Latest Report on REGN
Insiders Place Their Bets
In related news, Director Arthur F. Ryan sold 200 shares of the firm's stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $482,400. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,400 shares of company stock valued at $1,090,030 over the last 90 days. Insiders own 6.97% of the company's stock.
Regeneron Pharmaceuticals Stock Performance
Regeneron Pharmaceuticals stock opened at $828.50 on Tuesday. The firm's fifty day moving average price is $701.36 and its 200-day moving average price is $716.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock has a market cap of $85.30 billion, a P/E ratio of 20.48, a price-to-earnings-growth ratio of 1.42 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $847.00.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm's revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $12.81 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals's payout ratio is 9.29%.
About Regeneron Pharmaceuticals
(
Free Report)
Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Stories
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
